FINWIRES · TerminalLIVE
FINWIRES

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

By

Revolution Medicines (RVMD) should post "strong launch numbers" for pancreatic cancer drug Rasonque (daraxonrasib), which would serve as a key driver of its 2026 and 2027 revenue, UBS Securities said in a Thursday note.

The US Food and Drug Administration approved Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma, with the company to price the therapy at $39,800 for a 30-day supply.

Street consensus for the company's 2026 and 2027 revenue already increased following the approval, but the updated projections remain achievable, UBS said. Revolution Medicines already had 2,000 patients on its expanded access program as of Q2, the brokerage noted.

The consensus is for $152 million revenue in 2026 and $1.10 billion in 2027, while UBS estimates $193 million in 2026 and $1.91 billion in 2027, according to the note.

UBS also noted the upcoming phase 3 data on daraxonrasib in non-small cell lung cancer by year-end 2027 as Revolution Medicines' next major clinical catalyst.

UBS raised its price target on Revolution Medicines to $265 from $220, with a buy rating.

Price: $206.08, Change: $-15.07, Percent Change: -6.81%

Related Articles

Wire

Update: PagerDuty Q2 Adjusted Earnings, Revenue Rise; Company Plans 15% Workforce Cut

(Updates with job cuts in the penultimate paragraph.)PagerDuty (PD) reported Thursday Q2 adjusted earnings of $0.32 per diluted share, up from $0.30 a year earlier.Analysts polled by FactSet expected $0.31.Revenue for the quarter ended July 31 rose to $124.4 million from $123.4 million a year earlier.Analysts projected $123.3 million.The company expects Q3 adjusted EPS of $0.34 to $0.36 on revenue of $123 million to $125 million. Analysts project EPS of $0.34 on revenue of $124.4 million.PagerDuty expects 2027 adjusted EPS of $1.33 to $1.37 on revenue of $491.5 million to $496.5 million. Analysts project EPS of $1.32 on revenue of $494.2 million.In a regulatory filing, the company said it plans to cut 15% of its workforce as part of a restructuring and record non-recurring charges of $5.5 million to $7.5 million related to the move.PagerDuty shares fell 2.4% in after-hours trading.

$PD
Wire

Affirm Fiscal Q4 Earnings, Revenue Rise; Shares Gain After-Hours

Affirm Holdings (AFRM) reported fiscal Q4 net income late Thursday of $4.62 per diluted share, up from $0.20 a year earlierAnalysts polled by FactSet expected $0.35, if comparable.Revenue for the quarter ended June 30 was $1.17 billion, up from $876.4 million a year earlier.Analysts expected $1.11 billion.For fiscal Q1, the company expects revenue of $1.19 billion to $1.22 billion.Analysts are looking for $1.16 billion.Shares rose over 6% in after-hours activity.

$AFRM
Wire

Elastic Q1 Adjusted Earnings, Revenue Rise; Shares Surge After Hours

Elastic (ESTC) reported fiscal Q1 non-GAAP earnings late Thursday of $0.70 per diluted share, up from $0.60 a year earlier.Analysts polled by FactSet expected $0.58.Revenue in the three months ended July 31 rose to $478.1 million from $415.3 million a year earlier.Analysts projected $469.7 million.The company expects fiscal Q2 non-GAAP EPS of $0.80 to $0.82 on revenue of $486 million to $487 million.Analysts project EPS of $0.79 on revenue of $483.5 million.Elastic boosted fiscal 2027 guidance to non-GAAP EPS of $3.29 to $3.37 on revenue of $1.998 billion to $2.01 billion, up from the prior forecast of EPS of $3.21 to $3.29 on revenue of $1.985 billion to $2 billion.Analysts expect EPS of $3.24 on revenue of $1.996 billion.Elastic shares jumped 22% in after-hours trading.

$ESTC
Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says | FINWIRES